drugset / Trial / NCT00376428

Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients

NCT00376428

Phase 2 Terminated 20 enrolled Assistance Publique - Hôpitaux de Paris
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Suppression of stop mutations in the CFTR gene with parenteral gentamicin can be predicted in vitro and is associated with clinical benefit and significant modification of the CFTR-mediated chloride transport in nasal and sweat gland epithelium.

Timeline

Start
2003-01
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gentamicin Small molecule 10 mg/kg Intravenous

Indications